Democratic Republic of the Congo & Hilleman Laboratories

Democratic Republic of the Congo: The epicenter of the outbreak, facing a public health crisis with over 2,100 deaths and strained healthcare infrastructure. The government is coordinating the response but faces challenges from conflict and unpaid health workers.

Hilleman Laboratories: Developing a promising rVSV-based Bundibugyo vaccine, with WHO calling it the 'most promising' candidate. Its progress could provide a key tool against the outbreak.

Democratic Republic of the Congo: The Democratic Republic of the Congo is the epicenter of the outbreak, facing severe health and economic strain. The vaccine arrival is a positive step, but the country continues to suffer high mortality and disruption.

Hilleman Laboratories: Hilleman Laboratories is developing the rVSV Bundibugyo vaccine, described by WHO as the most promising candidate. Its success could be significant for the company and outbreak control.